Bolt-on acquisitions and mergers between Chinese biotechs and major drug makers had not yet come into fashion over the past year, although the two groups continued to pursue tie-ups in their efforts to continue with innovative drug development despite a sustained downward market.
Although Shijiazhuang-based major CSPC Pharmaceutical Group Limited, one of China’s largest generics giants, was in early 2022 poised to...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

